Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: Presenting as treatment-resistant candidiasis and chronic lung disease

Clinical Immunology

Volumn 164, Issue , 2016, Pages 1-9

  Dotta, Laura ^a   Scomodon, Omar ^a   Padoan, Rita ^b   Timpano, Silviana ^b   Plebani, Alessandro ^a   Soresina, Annarosa ^a   Lougaris, Vassilios ^a   Concolino, Daniela ^c   Nicoletti, Angela ^c   Giardino, Giuliana ^d   Licari, Amelia ^e   Marseglia, Gianluigi ^e   Pignata, Claudio ^d   Tamassia, Nicola ^f   Facchetti, Fabio ^a   Vairo, Donatella ^a   Badolato, Raffaele ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

Author keywords

Autoimmunity; Bronchiectasis; Chronic lung disease; Chronic mucocutaneous candidiasis; Gain of function STAT1; Lymphopenia

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE; STAT1 PROTEIN; VORICONAZOLE; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE; STAT1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; BRONCHIECTASIS; CANDIDIASIS; CHILD; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; ESOPHAGUS CANDIDIASIS; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; INFECTION PREVENTION; KIDNEY DISEASE; LYMPHOCYTOPENIA; MALE; MUCOCUTANEOUS CANDIDIASIS; PARASITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RISK FACTOR; VISCERAL LEISHMANIASIS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; CHRONIC DISEASE; COMPLICATION; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE; GENETICS; LUNG DISEASES; METABOLISM; MIDDLE AGED; MUTATION; PHOSPHORYLATION; VIRUS INFECTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AUTOIMMUNITY; AZOLES; BACTERIAL INFECTIONS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; CHILD; CHRONIC DISEASE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; LUNG DISEASES; LYMPHOPENIA; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; VIRUS DISEASES; YOUNG ADULT;

EID: 84955072089     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.12.010     Document Type: Article

References (33)

1. Liu L., Okada S., Kong X.-F., Kreins A.Y., Cypowyj S., Abhyankar A., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011, 208:1635-1648.
2. van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P., Joosten L.A.B., Gilissen C., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 2011, 365:54-61.
3. Boisson-Dupuis S., Kong X.-F., Okada S., Cypowyj S., Puel A., Abel L., et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. 2012, 24:364-378.
4. Puel A., Picard C., Cypowyj S., Lilic D., Abel L., Casanova J.-L. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?. Curr. Opin. Immunol. 2010, 22:467-474.
5. Averbuch D., Chapgier A., Boisson-Dupuis S., Casanova J.-L., Engelhard D. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-1. Pediatr. Infect. Dis. J. 2011, 30:352-355.
6. Vairo D., Tassone L., Tabellini G., Tamassia N., Gasperini S., Bazzoni F., et al. Severe impairment of IFN-γ and IFN-α responses in cells of a patient with a novel STAT1 splicing mutation. Blood 2011, 118:1806-1817.
7. Chapgier A., Boisson-Dupuis S., Jouanguy E., Vogt G., Feinberg J., Prochnicka-Chalufour A., et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2006, 2.
8. Bustamante J., Boisson-Dupuis S., Abel L., Casanova J.-L. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin. Immunol. 2014, 26:454-470.
9. Tanimura M., Dohi K., Hirayama M., Sato Y., Sugiura E., Nakajima H., et al. Recurrent inflammatory aortic aneurysms in chronic mucocutaneous candidiasis with a gain-of-function STAT1 mutation. Int. J. Cardiol. 2015, 196:88-90.
10. Sampaio E.P., Hsu A.P., Pechacek J., Bax H.I., Dias D.L., Paulson M.L., et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J. Allergy Clin. Immunol. 2013, 131:1624-1634.
11. Kumar N., Hanks M.E., Chandrasekaran P., Davis B.C., Hsu A.P., Van Wagoner N.J., et al. Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J. Allergy Clin. Immunol. 2014, 134:236-239.
12. Tóth B., Méhes L., Taskó S., Szalai Z., Tulassay Z., Cypowyj S., et al. Herpes in STAT1 gain-of-function mutation [corrected]. Lancet 2012, 379:2500.
13. Kilic S.S., Puel A., Casanova J.-L. Orf infection in a patient with Stat1 gain-of-function. J. Clin. Immunol. 2014, 35:80-83.
14. Uzel G., Sampaio E.P., Lawrence M.G., Hsu A.P., Hackett M., Dorsey M.J., et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J. Allergy Clin. Immunol. 2013, 131:1611-1623.
15. Sharfe N., Nahum A., Newell A., Dadi H., Ngan B., Pereira S.L., et al. Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. J. Allergy Clin. Immunol. 2014, 133:807-817.
16. Dotta L., Scomodon O., Padoan R., Timpano S., Plebani A., Soresina A., et al. Clinical and Immunological Data of Nine Patients with Chronic Mucocutaneous Candidiasis Disease 2015, (Data in Brief submitted for publication).
17. Den Dunnen J.T., Antonarakis E. Nomenclature for the description of human sequence variations. Hum. Genet. 2001, 109:121-124.
18. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11:1475-1489.
19. Soltész B., Tóth B., Shabashova N., Bondarenko A., Okada S., Cypowyj S., et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J. Med. Genet. 2013, 50:567-578.
20. Higgins E., Al Shehri T., McAleer M.A., Conlon N., Feighery C., Lilic D., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J. Allergy Clin. Immunol. 2015, 135:551-553.
21. Groth S., Stafanger G., Dirksen H., Andersen J.B., Falk M., Kelstrup M. Positive expiratory pressure (PEP-mask) physiotherapy improves ventilation and reduces volume of trapped gas in cystic fibrosis. Bull. Eur. Physiopathol. Respir. 1985, 21:339-343.
22. Hill K., Patman S., Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. Chron. Respir. Dis. 2010, 7:9-17.
23. Plebani A., Pinzani R., Startari R., Brusa D., Padoan R. Usefulness of chest physiotherapy with positive expiratory pressure (PEP)-mask in HIV-infected children with recurrent pulmonary infections. Acta Paediatr. 1992, 86(1997):1195-1197.
24. Stanojevic S., Wade A., Stocks J., Hankinson J., Coates A.L., Pan H., et al. Reference ranges for spirometry across all ages: a new approach. Am. J. Respir. Crit. Care Med. 2008, 177:253-260.
25. Simon M.R., Chinchilli V.M., Phillips B.R., Sorkness C.A., Lemanske R.F., Szefler S.J., et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J. Allergy Clin. Immunol. 2010, 126:527-534.
26. Yap V.L., Metersky M.L. New therapeutic options for noncystic fibrosis bronchiectasis. Curr. Opin. Infect. Dis. 2015, 28(2):171-176.
27. Yamazaki Y., Yamada M., Kawai T., Morio T., Onodera M., Ueki M., et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody, journal of immunology (Baltimore. MD 1950, 193(2014):4880-4887.
28. Wildbaum G., Shahar E., Katz R., Karin N., Etzioni A., Pollack S. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J. Allergy Clin. Immunol. 2013, 132:761-764.
29. Mizoguchi Y., Tsumura M., Okada S., Hirata O., Minegishi S., Imai K., et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J. Leukoc. Biol. 2014, 95:667-676.
30. Frans G., Moens L., Schaballie H., Van Eyck L., Borgers H., Wuyts M., et al. Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding. J. Allergy Clin. Immunol. 2014, 134(5):1209-1213.
31. Takezaki S., Yamada M., Kato M., Park M.-J., Maruyama K., Yamazaki Y., et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain, journal of immunology (Baltimore. MD 1950, 189(2012):1521-1526.
32. Crow Y.J. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr. Opin. Immunol. 2014, 32C:7-12.
33. Oftedal B.E., Hellesen A., Erichsen M.M., Bratland E., Vardi A., Perheentupa J., et al. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity 2015, 42:1185-1196.